Skip to content

The effect of barberry root on schizophrenia

Evaluating the effect of Berberry root (Berberis vulgaris) as Adjuvant Treatment on the prevention of atypical Antipsychotic-Induced metabolic syndrome in Patients With Schizophrenia: A triple-blind, Randomized, Placebo-controlled Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210425051074N1
Enrollment
106
Registered
2021-06-15
Start date
2021-06-05
Completion date
Unknown
Last updated
2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia. Schizophrenia

Interventions

Intervention 1: Intervention group: After obtaining written consent and explaining the study conditions, patients are asked to complete a demographic questionnaire that includes age, sex, duration of

Sponsors

Ahvaz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Early diagnosis of schizophrenia They must have recently sought treatment or not received any medication in the past three months Study subjects should be screened for metabolic syndrome. In fact, all patients should be screened for glucose levels, blood lipids, blood pressure, and waist circumference, and ultimately only those with no or at most two of these symptoms should be included in the study The patient is able to take medicine Receive written consent from the patient or parents to enter the study

Exclusion criteria

Exclusion criteria: Pregnant and lactating women Incidence of any side effects of the drug) stomach pain, diarrhea, constipation, bloating, headache, skin complications Existence of any severe and chronic physical diseases (brain, cardiovascular, neurological and seizure diseases, liver, diabetes, hypertension, hyperlipidemia, joints or history of substance use) Mental retardation People treated with antihypertensives, antihypertensives, anticoagulants, sedatives, and drugs that are metabolized by the liver.

Design outcomes

Primary

MeasureTime frame
Cholestrol. Timepoint: At the beginning of the study and three months later. Method of measurement: blood sample.;Triglyceride. Timepoint: At the beginning of the study and three months later. Method of measurement: blood sample.;Blood pressure. Timepoint: At the beginning of the study and three months later. Method of measurement: Hand pressure gauge.;Blood suger. Timepoint: At the beginning of the study and three months later. Method of measurement: blood sample.

Secondary

MeasureTime frame
Cholestrol. Timepoint: At the beginning of the study and 3 months later. Method of measurement: blood sample.;Blood pressur. Timepoint: At the beginning of the study and 3 months later. Method of measurement: Hand pressure gauge.;Blood suger. Timepoint: At the beginning of the study and 3 months later. Method of measurement: blood sample.;Waist size. Timepoint: At the beginning of the study and 3 months later. Method of measurement: meter.;Triglyceride. Timepoint: At the beginning of the study and 3 months later. Method of measurement: blood sample.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHamzeh Rostami

Ahvaz University of Medical Sciences

rostami-h@ajums.ac.ir+98 61 3374 3038

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026